Zivo Bioscience Partners to Boost Poultry Health with New Immune-Boosting Solution

Zivo Bioscience Partnered with Animal Health Companies to Advance Poultry

Image Credits: AInvest

Announcement

Zivo Bioscience, Inc., an agtech R&D and biotech company known for its nutritional products and development of therapeutic has partnered with a leading animal health company to invest in the advancement of ZIVO’s novel immune-boosting compounds. This will be used in various poultry market segments. This engagement might lead to expansion and fulfill the needs of companion and livestock animal species. Currently, Zivo and its partner have entered into two agreements governing independent studies that are introduced to expand and evaluate the use of ZIVO’s proprietary representing as an immune-enhancing biologics. This will boost the existing poultry vaccination strategies.

Agreements

The first agreement consists of a 42-day study, mainly focusing on coccidiosis, which is a parasitic disease. This disease is a challenge to poultry producers globally. This is a challenging study initiated to validate and confirm its previously identified effects of ZIVO’s compound that was recently co-administered with the partner’s vaccine. The partner’s vaccine consists of plasma samples and tissues to calculate performance parameters, which were not previously considered or examined. This clinical trial will cooperate with the regulatory approval process of the USDA’s Center for Veterinary Biologics. The trial will tick the commercial business box to make an official commercial agreement.

The second agreement covers a study to assess ZIVO’s compound with the help of models of several other viral diseases that might cause severe disadvantage to the commercial poultry industry. A disease with no cure will be considered for a study and characterized by a high mortality rate and rapid onset. The virus was chosen for its developed in vivo model, short study duration, and clinical endpoints. Introducing it as a representative model further serving the vast viral poultry disease. Though this study was interrupted by ZIVO’s old reported data that showed the spread of low-pathogenic avian influenza in treated birds and minimized severity.

The positive outcome will pave the way for broader research agreement to adopt additional dieases. The applications for virus treatment indicate an expansion of the economic value and therapeutic range of ZIVO’s immune-boosting compound.

Initiative

These two studies, according to the agreements, will be funded by the partner company. It will involve an investigation of various ZIVO product candidates for their potential to reduce the time between onset and immunization of protective immunity. The product's ability to protect birds during the risky situation between immunity and vaccination enhances the immune response.